| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 18, 2001
From the Leducq Center for Cardiovascular Research (M.L.L., J.G., M.A., P.L., R.T.L.), Cardiovascular Division, Department of Medicine, and the Department of Pathology (F.J.S., E.R.), Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; and Pfizer Central Research (L.L.-M., J.C., S.B., P.G.M.), Groton, Conn. * To whom correspondence should be addressed. E-mail: rlee{at}rics.bwh.harvard.edu.
BackgroundBroad
inhibition of matrix metalloproteinases (MMPs) attenuates left
ventricular remodeling after myocardial infarction (MI).
However, it is not clear if selective MMP inhibition strategies will be
effective or if MMP inhibition will impair angiogenesis after
MI. Methods and ResultsWe
used a selective MMP inhibitor (MMPi) that does not inhibit
MMP-1 in rabbits, which, like humans but unlike rodents, express MMP-1
as a major collagenase. On day 1 after MI, rabbits were
randomized to receive either inhibitor (n=10) or vehicle
(n=8). At 4 weeks after MI, there were no differences in infarct size
or collagen fractional area. However, MMPi reduced
ventricular dilation. The increase in
end-diastolic dimension from day 1 to week 4 was
3.1±0.5 mm for vehicle versus 1.3±0.3 mm for MMPi
(P<0.01). The increase in
end-systolic dimension was 2.8±0.5 mm for vehicle and
1.3±0.4 mm for MMPi
(P<0.05). Furthermore, MMPi
reduced infarct wall thinning; the minimal infarct thickness was
0.8±0.1 mm for vehicle and 1.6±0.3 mm for MMPi
(P<0.05). Interestingly, the
MMPi group had increased numbers of vessels in the subendocardial layer
of the infarct; the number of capillaries was increased in the
subendocardial layer (46±4 vessels/field versus 17±3 vessels/field
for vehicle; P<0.001), and the
number of arterioles was also increased (4.0±0.8 vessels/field versus
2.0±0.4 vessels/field for vehicle;
P<0.05).
ConclusionsMMP
inhibition attenuates left ventricular remodeling even when
the dominant collagenase MMP-1 is not inhibited;
furthermore, this selective MMP inhibition appears to increase rather
than decrease neovascularization in the
subendocardium.
Revised on November 29, 2001
Accepted on December 14, 2001
Selective Matrix Metalloproteinase Inhibition
Reduces Left Ventricular Remodeling but Does Not Inhibit
Angiogenesis After Myocardial Infarction
This article has been cited by other articles:
![]() |
D. Kelly, S. Q. Khan, M. Thompson, G. Cockerill, L. L. Ng, N. Samani, and I. B. Squire Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur. Heart J., July 8, 2008; (2008) ehn315v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Uemura, M. Li, T. Tsutsumi, T. Yamazaki, T. Kawada, A. Kamiya, M. Inagaki, K. Sunagawa, and M. Sugimachi Efferent vagal nerve stimulation induces tissue inhibitor of metalloproteinase-1 in myocardial ischemia-reperfusion injury in rabbit Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2254 - H2261. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Aupperle, J. Garbade, A. Schubert, M. Barten, S. Dhein, H.-A Schoon, and F.-W Mohr Effects of Autologous Stem Cells on Immunohistochemical Patterns and Gene Expression of Metalloproteinases and Their Tissue Inhibitors in Doxorubicin Cardiomyopathy in a Rabbit Model Vet. Pathol., July 1, 2007; 44(4): 494 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mukherjee, J. T. Mingoia, J. A. Bruce, J. S. Austin, R. E. Stroud, G. P. Escobar, D. M. McClister Jr, C. M. Allen, M. A. Alfonso-Jaume, M. E. Fini, et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2216 - H2228. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. B. Engel, P. C. H. Hsieh, R. T. Lee, and M. T. Keating FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction PNAS, October 17, 2006; 103(42): 15546 - 15551. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsusaka, T. Ide, S. Matsushima, M. Ikeuchi, T. Kubota, K. Sunagawa, S. Kinugawa, and H. Tsutsui Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice Cardiovasc Res, June 1, 2006; 70(3): 457 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. He, D. M. Opland, K. J. Way, K. Ueki, N. Bodyak, P. M. Kang, S. Izumo, R. N. Kulkarni, B. Wang, R. Liao, et al. Regulation of Vascular Endothelial Growth Factor Expression and Vascularization in the Myocardium by Insulin Receptor and PI3K/Akt Pathways in Insulin Resistance and Ischemia Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 787 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Janssens and H. R. Lijnen What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res, February 15, 2006; 69(3): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window Cardiovasc Res, February 15, 2006; 69(3): 604 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, G. P. Escobar, L. W. Dobrucki, D. K. Goshorn, S. Bouges, J. T. Mingoia, D. M. McClister Jr., H. Su, J. Gannon, C. MacGillivray, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H232 - H239. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Su, F. G. Spinale, L. W. Dobrucki, J. Song, J. Hua, S. Sweterlitsch, D. P. Dione, P. Cavaliere, C. Chow, B. N. Bourke, et al. Noninvasive Targeted Imaging of Matrix Metalloproteinase Activation in a Murine Model of Postinfarction Remodeling Circulation, November 15, 2005; 112(20): 3157 - 3167. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsusaka, M. Ikeuchi, S. Matsushima, T. Ide, T. Kubota, A. M. Feldman, A. Takeshita, K. Sunagawa, and H. Tsutsui Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1858 - H1864. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Perlini, G. Palladini, I. Ferrero, R. Tozzi, S. Fallarini, A. Facoetti, R. Nano, F. Clari, G. Busca, R. Fogari, et al. Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload Hypertrophy Hypertension, November 1, 2005; 46(5): 1213 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, D. K. Goshorn, C. E. Squires, G. P. Escobar, J. W. Hendrick, J. T. Mingoia, S. E. Sweterlitsch, and F. G. Spinale Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function Cardiovasc Res, May 1, 2005; 66(2): 410 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, C.-H. Tung, J. R. Allport, S. Chen, R. Weissleder, and P. L. Huang Near-Infrared Fluorescent Imaging of Matrix Metalloproteinase Activity After Myocardial Infarction Circulation, April 12, 2005; 111(14): 1800 - 1805. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Heymans, F. Lupu, S. Terclavers, B. Vanwetswinkel, J.-M. Herbert, A. Baker, D. Collen, P. Carmeliet, and L. Moons Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in Mice Am. J. Pathol., January 1, 2005; 166(1): 15 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Ikonomidis, J. W. Hendrick, A. M. Parkhurst, A. R. Herron, P. G. Escobar, K. B. Dowdy, R. E. Stroud, E. Hapke, M. R. Zile, and F. G. Spinale Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H149 - H158. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sundstrom, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, D. B. Sawyer, D. A. Siwik, W. S. Colucci, P. Sutherland, P. W.F. Wilson, et al. Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures: The Framingham Heart Study Circulation, June 15, 2004; 109(23): 2850 - 2856. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Barandon, T. Couffinhal, P. Dufourcq, J. Ezan, P. Costet, D. Daret, C. Deville, and C. Duplaa Frizzled A, a novel angiogenic factor: promises for cardiac repair Eur. J. Cardiothorac. Surg., January 1, 2004; 25(1): 76 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Chapman and F. G. Spinale Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H1 - H10. [Full Text] [PDF] |
||||
![]() |
L. Barandon, T. Couffinhal, J. Ezan, P. Dufourcq, P. Costet, P. Alzieu, L. Leroux, C. Moreau, D. Dare, and C. Duplaa Reduction of Infarct Size and Prevention of Cardiac Rupture in Transgenic Mice Overexpressing FrzA Circulation, November 4, 2003; 108(18): 2282 - 2289. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, A. S. Lowry, T. P. O'Neill, et al. Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling Circulation, October 7, 2003; 108(14): 1753 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Villarreal, M. Griffin, J. Omens, W. Dillmann, J. Nguyen, and J. Covell Early Short-Term Treatment With Doxycycline Modulates Postinfarction Left Ventricular Remodeling Circulation, September 23, 2003; 108(12): 1487 - 1492. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, J. Yoshioka, C. MacGillivray, S. Muangman, J. Gannon, A. Verghese, M. Aikawa, P. Libby, S. M. Krane, and R. T. Lee Effect of a Cleavage-Resistant Collagen Mutation on Left Ventricular Remodeling Circ. Res., August 8, 2003; 93(3): 238 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hayashidani, H. Tsutsui, M. Ikeuchi, T. Shiomi, H. Matsusaka, T. Kubota, K. Imanaka-Yoshida, T. Itoh, and A. Takeshita Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1229 - H1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Wilson, S. L. Moainie, J. M. Baskin, A. S. Lowry, A. M. Deschamps, R. Mukherjee, T. S. Guy, M. G. St John-Sutton, J. H. Gorman III, L. H. Edmunds Jr, et al. Region- and Type-Specific Induction of Matrix Metalloproteinases in Post-Myocardial Infarction Remodeling Circulation, June 10, 2003; 107(22): 2857 - 2863. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Yarbrough, R. Mukherjee, T. A. Brinsa, K. B. Dowdy, A. A. Scott, G. P. Escobar, C. Joffs, D. G. Lucas, F. A. Crawford Jr, and F. G. Spinale Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 602 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. J. M. Creemers, J. N. Davis, A. M. Parkhurst, P. Leenders, K. B. Dowdy, E. Hapke, A. M. Hauet, P. G. Escobar, J. P. M. Cleutjens, J. F. M. Smits, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H364 - H371. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Thompson and I. B. Squire Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological? Cardiovasc Res, June 1, 2002; 54(3): 495 - 498. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |